Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr Foresees Plan B Launch In The Fall Under “Best” Circumstances

This article was originally published in The Pink Sheet Daily

Executive Summary

The company expects that labeling discussions will last three to four months following an “approvable” decision by the May 21 user fee date. Barr’s promotional efforts will focus on educating health care providers.

You may also be interested in...



Plan B OTC Submission Deemed "Not Approvable"

Barr will have to detail a mechanism for drugstores to screen women less than 16 years of age for nonprescription use of the emergency contraceptive. FDA's decision goes against the recommendation of its advisory panels.

Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors

The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel